leisure time -WSS

leisure time

author：fashion 2025-08-19 18:06:49 - browse：92

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Congress likely to miss an opportunity to fix drug shortages issue

WSS

Supreme Court mifepristone arguments center on docs' right to sue

Abortion pill case raises question: who can sue the FDA?

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Readout LOUD podcast: mifepristone case, GLP

Supreme Court mifepristone arguments center on docs' right to sue

Study says nonprofit hospitals fall short in charity care spending

Wikipedia

leisure time

knowledge

Bright Health sells Medicare Advantage business to Molina

J&J expands global access to TB drug amid advocacy campaign

Apple is now the first public company to be valued at $3 trillion

Merck drug for rare lung condition set for approval in U.S.

United colonoscopy coverage change 'may cost lives,' doctors say

Donor acceptance rates hint at racial, gender bias in heart transplants: study

In age of alternative facts, a scholarly course on calling out crap

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

focus

Global childhood vaccinations edge closer to pre

Washington mulls new rules to avert another Change Healthcare

Celiac disease study examines precisely how gluten triggers injury

Food as medicine: Medically tailored meals may get standardized

Grail faces three suits alleging harassment, retaliation

Eliminate the waiting period for sterilization covered by Medicaid

explore

focus

Wikipedia

focus